Literature DB >> 1976304

Retroviral-mediated gene transfer of the leukocyte integrin CD18 subunit.

A L Back1, W W Kwok, M Adam, S J Collins, D D Hickstein.   

Abstract

Children with leukocyte adherence deficiency (LAD) exhibit heterogeneous defects in the leukocyte integrin CD18 subunit that prevent surface expression of functional CD11/CD18 leukocyte integrin adherence complexes. We used a retroviral vector, designated LCD18SN, to transfer the CD18 cDNA into K562 human myeloid leukemia cells and into EBV B-cells from a child with LAD. Transfer of the LCD18SN retroviral construct, which expresses the CD18 cDNA from the Moloney Murine leukemia virus (MoMLV) long terminal repeat (LTR), into K562 cells resulted in relatively high levels of CD18 mRNA and intracellular protein. Retroviral-mediated gene transfer of CD18 into LAD EBV B-cells resulted in low, but readily measurable, levels of surface expression of the CD11a/CD18 complex in these previously deficient lymphocytes. The reconstitution of surface expression of the CD11a/CD18 complex by gene transfer of the CD18 cDNA into LAD EBV B-cells indicates that this syndrome represents a candidate disorder for gene therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1976304     DOI: 10.1016/0006-291x(90)91215-e

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  Mechanisms and consequences of leukocyte-endothelial interaction.

Authors:  J M Harlan; N B Vedder; R K Winn; C L Rice
Journal:  West J Med       Date:  1991-10

Review 2.  Gene therapy of primary immunodeficiencies.

Authors:  F Candotti; R M Blaese
Journal:  Springer Semin Immunopathol       Date:  1998

3.  Lentiviral vectors incorporating a human elongation factor 1alpha promoter for the treatment of canine leukocyte adhesion deficiency.

Authors:  E J R Nelson; L M Tuschong; M J Hunter; T R Bauer; T H Burkholder; D D Hickstein
Journal:  Gene Ther       Date:  2010-02-18       Impact factor: 5.250

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.